ArticleeLife2017
Suppression of
Open access · goldAbstract read
In one paragraph
Article in eLife, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 53 citations in OpenAlex.
- C9orf72 ALS-causing mutations lead to mislocalization and aggregation of nucleoporin Nup107 into stress granules.FEBS letters · 2025Article
- Aberrant splicing exonizes C9orf72 repeat expansion in ALS/FTD.Nature neuroscience · 2025Article
- Targeting GeneInternational journal of molecular sciences · 2025Review
- RNA dysregulation in neurodegenerative diseases.The EMBO journal · 2025Review
- Article
- Zfp106 binds to G-quadruplex RNAs and inhibits RAN translation and formation of RNA foci caused by G4C2 repeats.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Reversal ofProceedings of the National Academy of Sciences of the United States of America · 2024Article
- RNA-Binding Proteins: A Role in Neurotoxicity?Neurotoxicity research · 2023Review
- Mitochondrial Dysfunction in Repeat Expansion Diseases.Antioxidants (Basel, Switzerland) · 2023Review
- Advances in the Structure of GGGGCC Repeat RNA Sequence and Its Interaction with Small Molecules and Protein Partners.Molecules (Basel, Switzerland) · 2023Review
- Partners in crime: Proteins implicated in RNA repeat expansion diseases.Wiley interdisciplinary reviews. RNA · 2022Review
- NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility.Nature communications · 2022Article
- Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives.International journal of molecular sciences · 2021Review
- Fly for ALS: Drosophila modeling on the route to amyotrophic lateral sclerosis modifiers.Cellular and molecular life sciences : CMLS · 2021Review
- Control of ribosomal protein synthesis by the Microprocessor complex.Science signaling · 2021Article
- Amyotrophic Lateral Sclerosis Genes inInternational journal of molecular sciences · 2021Review
- Altered Phase Separation and Cellular Impact inFrontiers in cellular neuroscience · 2021Article
- RNA-mediated toxicity in C9orf72 ALS and FTD.Neurobiology of disease · 2020Review
- Genome Wide Analysis Points towards Subtype-Specific Diseases in Different Genetic Forms of Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2020Article
- Role of the C9ORF72 Gene in the Pathogenesis of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.Neuroscience bulletin · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Barbara CelonaCardiovascular Research Institute, University of California, San Francisco, San Francisco, United States.
John von DollenDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.
Sarat C VatsavayaiDepartment of Neurology, University of California, San Francisco, San Francisco, United States.
Risa KashimaCardiovascular Research Institute, University of California, San Francisco, San Francisco, United States.
Jeffrey R JohnsonDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.
Amy A TangDepartment of Pathology, University of California, San Francisco, San Francisco, United States.
Akiko HataCardiovascular Research Institute, University of California, San Francisco, San Francisco, United States.
Bruce L MillerDepartment of Neurology, University of California, San Francisco, San Francisco, United States.
Eric J HuangDepartment of Pathology, University of California, San Francisco, San Francisco, United States.
Nevan J KroganDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.
William W SeeleyDepartment of Neurology, University of California, San Francisco, San Francisco, United States.
Brian L BlackCardiovascular Research Institute, University of California, San Francisco, San Francisco, United States.ORCID 0000-0002-6664-8913
University of California, San Francisco · US
Funding
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2MPrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, YADONG · 2004 to 2018
$27.1MTranscriptional Networks During Cardiac DifferentiationP01HL089707 · NHLBI · J. DAVID GLADSTONE INSTITUTES · PI SRIVASTAVA, DEEPAK · 2008 to 2017
$20.4MRegulation of cardiovascular transcriptionR01HL064658 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BLACK, BRIAN L · 2000 to 2019
$5.4MMechanisms of HIPK2 in neurodegenerationR01NS098516 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, ERIC J · 2016 to 2020
$1.7MMechanisms of ER Stress and Neurodegeneration in Parkinson's DiseaseI01BX001108 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI Eric J Huang · 2011 to 2026
–ER Stress-induced Neurodegeneration as Therapeutic Targets for ALSI01RX002133 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI HUANG, ERIC J · 2016 to 2019
–BLRD VA I01 BX001108NHLBI NIH HHS P01 HL089707NHLBI NIH HHS R01 HL064658NIA NIH HHS P01 AG019724NIA NIH HHS P50 AG023501NINDS NIH HHS R01 NS098516RRD VA I01 RX002133
Abstract
Expanded GGGGCC repeats in the first intron of the
Indexed as
Adaptor Proteins, Signal TransducingAmyotrophic Lateral SclerosisAnimalsC9orf72 ProteinDisease Models, AnimalDNA-Binding ProteinsDrosophilaGenetic Complementation TestMice, KnockoutMice, TransgenicProtein BindingProtein Interaction MappingRNA-Binding Protein FUSRNA-Binding ProteinsAdaptor Proteins, Signal TransducingC9orf72 ProteinC9orf72 protein, mouseDNA-Binding ProteinsFUS protein, mouseRNA-Binding Protein FUSRNA-Binding ProteinsTardbp protein, mouseZfp106 protein, mouseD. melanogasterknockout animalsmouseneurodegenerationneuroscienceRNA binding proteintransgenic animalszinc finger protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.